Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 16/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23724698 | 0.90 | METTL3 (0.47) | METTL3KDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL23724737 | 0.90 | METTL3 (0.47) | METTL3KDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL23724700 | 0.90 | METTL3 (0.47) | METTL3KDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL30433213 | 0.78 | DRD4 (0.53) | METTL3KDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL30432621 | 0.78 | DRD4 (0.53) | METTL3KDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL23726593 | 0.74 | KDM4E (0.45) | KDM4ECD274PDCD1LG2PDCD1 | |
| SCHEMBL30433263 | 0.73 | METTL3 (0.56) | METTL3KDM4E | |
| SCHEMBL30433035 | 0.73 | ALDH1A1 (0.45) | METTL3KDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL30433498 | 0.71 | METTL3 (0.58) | METTL3KDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL30433547 | 0.71 | METTL3 (0.57) | METTL3KDM4EADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | METTL3 773/4885KDM4E 224/4885ADORA3 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.